Abstract
When you talk to Marcus Quack, the DACH managing director of Revvity, and ask him what the few-month-old company actually does, he first has to take a deep breath. Previously, the company was still associated with PerkinElmer, whose applied, food and enterprise services were bought for almost 2.5 billion US dollars by the private equity company New Mountain Capital. The new scientific solutions company Revvity, on the other hand, continues to support pharmaceutical and biotech companies as well as diagnostics labs, universities and governments under a new name. ‚Monitor Versorgungsforschung‘ spoke with Marcus Quack about the company‘s rather lofty goals and a possible link to health services research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
